Coherus Historical Financial Ratios
| CHRS Stock | USD 1.22 0.04 3.17% |
Coherus BioSciences is presently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 388 or Invested Capital of 0.0 will help investors to properly organize and evaluate Coherus BioSciences financial condition quickly.
Coherus |
About Coherus Financial Ratios Analysis
Coherus BioSciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Coherus BioSciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Coherus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Coherus BioSciences history.
Coherus BioSciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Coherus BioSciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Coherus BioSciences sales, a figure that is much harder to manipulate than other Coherus BioSciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Coherus BioSciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Coherus BioSciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.At this time, Coherus BioSciences' Days Sales Outstanding is comparatively stable compared to the past year. Inventory Turnover is likely to gain to 2.73 in 2024, whereas PTB Ratio is likely to drop (1.70) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 10.88 | 12.95 | 10.81 | 12.85 | Receivables Turnover | 2.65 | 1.92 | 0.99 | 0.94 |
Coherus BioSciences fundamentals Correlations
Click cells to compare fundamentals
Coherus BioSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Coherus BioSciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 3.52 | 2.61 | 3.69 | 2.91 | 1.22 | 1.16 | |
| Ptb Ratio | 11.92 | 4.42 | 12.32 | (4.47) | (1.62) | (1.7) | |
| Book Value Per Share | 1.51 | 3.93 | 1.3 | (1.77) | (2.05) | (1.95) | |
| Free Cash Flow Yield | 0.0123 | 0.12 | (0.0322) | (0.4) | (0.56) | (0.53) | |
| Operating Cash Flow Per Share | 0.41 | 2.16 | (0.5) | (3.11) | (1.86) | (1.95) | |
| Stock Based Compensation To Revenue | 22.36 | 0.0943 | 0.0802 | 0.16 | 0.24 | 0.17 | |
| Capex To Depreciation | 3.96 | 2.44 | 0.37 | 0.55 | 0.0754 | 0.0717 | |
| Pb Ratio | 11.92 | 4.42 | 12.32 | (4.47) | (1.62) | (1.7) | |
| Ev To Sales | 3.53 | 2.32 | 3.66 | 4.84 | 2.69 | 2.55 | |
| Free Cash Flow Per Share | 0.22 | 2.06 | (0.51) | (3.13) | (1.86) | (1.95) | |
| Roic | 0.37 | 0.22 | (0.56) | (0.86) | (0.72) | (0.69) | |
| Inventory Turnover | 0.31 | 0.41 | 0.62 | 0.61 | 2.6 | 2.73 | |
| Net Income Per Share | 1.29 | 1.85 | (4.06) | (4.21) | (2.53) | (2.65) | |
| Days Of Inventory On Hand | 1.2K | 893.33 | 591.01 | 599.2 | 140.38 | 264.75 | |
| Payables Turnover | 0.66 | 2.48 | 3.56 | 6.08 | 4.62 | 6.61 | |
| Sales General And Administrative To Revenue | 0.37 | 0.28 | 0.49 | 0.89 | 0.8 | 0.76 | |
| Research And Ddevelopement To Revenue | 0.26 | 0.3 | 1.11 | 0.94 | 0.43 | 0.4 | |
| Capex To Revenue | 0.0362 | 0.0148 | 0.003947 | 0.009662 | 0.001112 | 0.001056 | |
| Cash Per Share | 2.55 | 7.58 | 5.53 | 2.47 | 1.25 | 1.19 | |
| Pocfratio | 44.25 | 8.05 | (32.17) | (2.55) | (1.79) | (1.7) | |
| Interest Coverage | 6.12 | 7.39 | (11.49) | (7.91) | (5.01) | (5.26) | |
| Capex To Operating Cash Flow | 0.45 | 0.0458 | (0.0344) | (0.008456) | (0.001635) | (0.001554) | |
| Pfcf Ratio | 81.16 | 8.44 | (31.1) | (2.53) | (1.79) | (1.7) | |
| Days Payables Outstanding | 555.37 | 147.3 | 102.41 | 60.03 | 78.97 | 75.02 | |
| Income Quality | 0.32 | 1.17 | 0.13 | 0.83 | 0.74 | 0.52 | |
| Roe | 0.85 | 0.47 | (3.13) | 2.38 | 1.23 | 1.97 | |
| Ev To Operating Cash Flow | 44.27 | 7.16 | (31.93) | (4.24) | (3.95) | (3.76) | |
| Pe Ratio | 13.97 | 9.39 | (3.93) | (1.88) | (1.32) | (1.38) | |
| Return On Tangible Assets | (2.18) | 0.22 | 0.16 | (0.45) | (0.69) | (0.43) | |
| Ev To Free Cash Flow | 81.21 | 7.51 | (30.87) | (4.2) | (3.95) | (3.75) | |
| Earnings Yield | 0.0716 | 0.11 | (0.25) | (0.53) | (0.76) | (0.72) | |
| Intangibles To Total Assets | 0.008713 | 0.004233 | 0.005245 | 0.0123 | 0.11 | 0.12 | |
| Net Debt To E B I T D A | 0.006467 | (0.85) | 0.0342 | (1.59) | (1.95) | (1.85) | |
| Current Ratio | 3.26 | 9.69 | 8.02 | 7.65 | 1.43 | 1.36 | |
| Tangible Book Value Per Share | 1.46 | 3.88 | 1.25 | (1.85) | (2.82) | (2.67) | |
| Graham Number | 6.62 | 12.8 | 10.88 | 12.95 | 10.81 | 12.85 | |
| Shareholders Equity Per Share | 1.51 | 3.93 | 1.3 | (1.77) | (2.05) | (1.95) | |
| Debt To Equity | 1.7 | 1.44 | 4.18 | (3.43) | (2.45) | (2.32) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.